Qutaiba I.

Investigates treatment of severe lung infections such as chronic pulmonary aspergillosis.

Also evaluates outcomes in patients with community-acquired pneumonia and viral pneumonia including COVID‑19.

• Antifungal protocols for chronic pulmonary aspergillosis
• Immunomodulation in severe community-acquired pneumonia
• Hemodynamic support in sepsis‑induced hypotension

The program evaluates novel vasopressor strategies for sepsis‑induced hypotension.

Studies complications of liver disease such as hepatic encephalopathy.

Research also addresses hematologic conditions like myelodysplastic syndrome.

Additional focus is placed on cardiac decompensation, specifically chronic decompensated heart failure.

• Rifaximin efficacy in hepatic encephalopathy
• Erythropoietin use in low‑risk myelodysplastic syndrome
• Integrated management of chronic decompensated heart failure

Molecular profiling focuses on IDH1 mutation in marrow disorders.

Targets inflammatory joint disease, notably rheumatoid arthritis.

Also addresses hemolytic disorders such as autoimmune hemolytic anemia.

• Dual anti‑TNF and JAK inhibition for rheumatoid arthritis
• Therapeutic approaches to autoimmune hemolytic anemia
• Safety of biologics under sustained immunosuppression

Clinical trials assess outcomes under sustained immunosuppression conditions.

Concentrates on squamous cell malignancies of the upper aerodigestive tract, including oropharyngeal carcinoma.

Research includes preservation of function in laryngeal cancer through multimodal therapy.

• EGFR‑targeted radiochemotherapy for oropharyngeal carcinoma
• Organ‑preserving protocols in laryngeal cancer
• Checkpoint blockade in head and neck squamous cell carcinoma

Efforts aim to improve survival in head and neck squamous cell carcinoma through combined modalities.